




RealRate

PHARMACEUTICAL 2021

Magenta Therapeutics Inc.
Rank 228 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Magenta Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Magenta Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 164% points. The greatest weakness of Magenta Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 116% points.

The company's Economic Capital Ratio, given in the ranking table, is -163%, being 192% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	151,527
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,430
Liabilities, Non-Current	0
Other Assets	1,780
Other Compr. Net Income	-31
Other Expenses	0
Other Liabilities	6,283
Other Net Income	0
Property and Equipment	8,312
Research and Development	50,615
Revenues	3,766
Selling, General and Administrative Expense	28,087

Output Variable	Value in 1000 USD
Assets	161,619
Liabilities	17,713
Expenses	78,702
Stockholders Equity	143,906
Net Income	-74,936
Comprehensive Net Income	-74,952
Economic Capital Ratio	-163%